Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy and Safety of AD-224
Sponsor: Addpharma Inc.
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-224
Official title: A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients with Essential Hypertension
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
252
Start Date
2024-04-15
Completion Date
2025-07
Last Updated
2025-02-04
Healthy Volunteers
No
Conditions
Interventions
AD-224A
PO, Once daily, 8weeks
AD-224B
PO, Once daily, 8weeks
AD-224C
PO, Once daily, 8weeks
Placebo of AD-224A
PO, Once daily, 8weeks
Placebo of AD-224B
PO, Once daily, 8weeks
Placebo of AD-224C
PO, Once daily, 8weeks
Locations (1)
Seoul National University Bundang Hospital
Seongnam-si, South Korea